The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Roche; Tesaro
Travel, Accommodations, Expenses - Boehringer Ingelheim; Celgene; Roche
 
Expert Testimony - Boehringer Ingelheim; Lilly
Travel, Accommodations, Expenses - Celgene; Gilead Sciences; Lilly; SERVIER
Nintedanib plus docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Preliminary efficacy and safety results of the non-interventional study VARGADO.
 
Christian Grohé
Honoraria - Abbvie; AstraZeneca; Boehringer Ingelheim; Lilly; MSD Oncology; Novartis; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; MSD Oncology
Research Funding - Abbvie (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb; Roche
 
Wolfgang Blau
No Relationships to Disclose
 
Wolfgang Gleiber
Consulting or Advisory Role - Boehringer Ingelheim; MSD
Travel, Accommodations, Expenses - Boehringer Ingelheim; MSD
 
Siegfried Haas
Research Funding - Boehringer Ingelheim (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; PharmaMar
 
Harald Mueller-Huesmann
No Relationships to Disclose
 
Mathias Schulze
Travel, Accommodations, Expenses - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; MSD Oncology; Novartis; Roche
 
Judith Atz
Employment - Boehringer Ingelheim
 
Rolf Kaiser
Employment - Boehringer Ingelheim
Patents, Royalties, Other Intellectual Property - Boehringer Ingelheim